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ABSTRACT 
SYSTEMIC AND STRENGTH EFFECTS: EXPERIMENTAL 
CONCENTRATIONS OF TOPICAL MENTHOL 
Lee J. Winchester 
August 9, 2010 
Menthol has been regularly utilized as a treatment in sports related injuries 
for many years, yet little is known about its physiological interactions or its effect 
on performance. Our previous study indicates that topically applied menthol may 
cause an acute decrease in blood flow and may improve strength capabilities. 
The purpose of this study is to examine the effects of two different concentrations 
of menthol (3.5% and 10%) on systemic blood flow and strength. 16 subjects 
participated in this 4 week study examining blood flow and strength effects after 
menthol or control treatment. Results indicate that the 3.5% menthol causes a 
significant «.05) decrease in blood flow, and arterial diameter in the treated leg, 
and decreased blood flow in the untreated leg. 10% menthol treatment 
attenuates the statistically significant increase in blood flow observed with 
Control treatment, and significantly decreases arterial diameter in the treated leg. 
Results indicate that menthol is capable of suppressing arterial blood flow locally 
and systemically. 
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Menthol is a heavily researched agent that is found in a variety of different 
products. Menthol is typically found as the active ingredient in many pain/burn 
relief gels such as Biofreeze, IcyHot, etc. It is a terpene compound that is well 
known for its cold or heat sensations as well as its anti-nociceptive and 
counterirritant properties [1-3]. As an additive in topical ointments, it is utilized to 
soothe the effects of burns, muscle soreness, and even joint pain [1, 3]. This 
could playa crucial role in sideline treatment of soft tissue injuries during an 
athletic event [4, 5]. If an athlete becomes injured, immediate and effective 
treatment must be applied to help sustain their performance capabilities and 
prevent further injuries. Although these effects of mentholated ointments are of 
common knowledge, detailed mechanisms behind these effects, as well as other 
potential effects, are not well established. 
With mentholated products being so widely utilized by consumers, one 
has to contemplate what impact menthol application has on the individual's 
normal physiological functions and physical performance. It has been 
demonstrated that menthol may affect the functional ability of certain cellular ion 
channels, leading to variations in nerve action potential formation [2, 6-12]. More 
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recent research has demonstrated that menthol may even impact blood flow in 
the arterial and cutaneous circulation [13-15]. These effects have led our lab to 




Menthol effects regular physiological function in numerous ways. It has 
been shown to alter the nervous responses of somatosensory receptors [1-3, 6, 7, 
9, 11, 12, 16-18], elicit changes in local and cellular vasoconstrictor responses [8, 
10, 13, 15, 19-22], and consequently attenuates the natural physiological 
inflammatory cascade [23-25]. Complete mechanisms for each of these 
responses are not clearly understood. Nevertheless, recent research has started 
to explore menthol's physiological interactions that display these functional 
characteristics. 
It is now understood that pain is sensed when an effector stimulates 
somatosensory receptors. Nociceptors, or pain receptors, trigger an action 
potential that stimulates the body to make adjustments either via the spinal cord, 
or the upper CNS. This action potential is caused by depolarization of the nerve 
cell body through an influx of sodium ions via voltage-operated sodium channels 
[2]. Research has shown that the possible anti nociceptive effects of menthol 
could be due to the blocking of these sodium channels [2]. Human skeletal 
muscle tissue was sampled, and electric stimulus was applied after tissue was 
exposed to menthol. At various application strengths, inactivated sodium 
channels were measured to determine the effect on depolarization. It was 
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demonstrated that the menthol acted as a block of the alpha subunit of voltage 
gated sodium channels, therefore causing hyperpolarization of the nervous 
membrane and a block in the signal of pain transduction [2]. 
Another study demonstrates the anti nociceptive effects of menthol by 
placing mice on a hotplate and determining pain threshold via observation of 
painfully stimulated behavior. This study suggests that the temporary pain relief 
from menthol was as effective as morphine for the hot plate test [1]. It is 
suggested that menthol selectively activates central K-opioid receptors, which led 
to this increase in pain threshold [1]. 
Menthol has many other noted effects as well, such as temperature 
sensations, which are a display of thermoreceptor excitation [6, 7,11, 12, 17,26]. 
Menthol generates feelings of cold via the transient receptor potential family of 
ion channels or (TRP's). TRP's are found throughout the body, but TRPM8, 
found mainly within thermosensitive neurons, is known to be commonly effected 
by menthol [9, 16, 18, 27-29]. Utilization of calcium imaging techniques has 
demonstrated that upon the application of menthol to cloned TRPM8 cells, a 
heavy intracellular influx of calcium ions caused depolarization due to the 
opening of non-selective calcium permeable cation channels [9, 16, 18, 27-29]. 
This nervous transduction leads to the thermo-sensation that is recognized from 
menthol application. However, menthol is not a direct effector of this calcium 
channel stimulation. Phosphatidylinositol 4,5 bisphosphate or PI(4,5)P2 is a 
compound that is thought to activate TRPM8 channels, as well as other calcium 
cation channels throughout the body. Rohacs et al has demonstrated that 
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application of menthol causes a direct sensitization of TRPM8 to the effects of 
PI(4,5)P2 [28]. This increase in sensitization is what leads to the excitation 
properties of thermosensation via menthol application. 
Under certain circumstances, menthol exacerbates cold response to the 
point of innocuous cold nociception, typically referred to as cold allodynia [6, 7, 
11,12,17,26]. It has been demonstrated that menthol propagates painful cold 
stimuli by attenuating the actions of A-delta sensory fibers [12]. A-delta fibers are 
responsible for painless cold transmission and their inhibitory effects on C 
nociceptor fibers. With menthol present, A-delta fibers become inactive, and C 
nociceptors transmit cold pain. 
Group III and IV muscle afferents physically correspond to A-delta and C 
nociceptor fibers respectively [10]. The vascular pressor response is controlled 
in part by the group III and IV afferent fibers. Several studies demonstrate that 
menthol's indirect inhibition of the group III afferents attenuate the pressor 
response elicited by muscle contraction and cold stimuli [8, 10]. Significant 
decreases in mean arterial pressure were observed at 20 minutes post 
application [8, 10], with one study showing significant effects even after 40 
minutes post treatment [8]. 
These findings correspond with menthol's ability to cause arterial 
vasoconstriction [19-22]. Cold stimulation causes an increased production of 
mitochondrial reactive oxygen species (RDS) [20]. RDS have been shown to 
activate a Rho A, an inactive protein that binds with GTP and forms Rho kinase 
[19]. Rho kinase then translocates a2c adrenergic receptors from the golgi to the 
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cell plasma membrane. Norepinephrine activates the a2c adrenergic receptors via 
sympathetic reflex of the muscle afferents, creating arterial vasoconstriction [21]. 
Rho kinase elicits further vasoconstriction by inhibiting actions of myosin light 
chain phosphatase in vascular smooth muscle (VSM) cells [19, 30]. This allows 
myosin light chain kinase to phosphorylate regulatory myosin light chain proteins, 
allowing for sensitization of calcium and contraction of the VSM cells. 
Adrenergic stimulation is an established generator of arterial 
vasoconstriction [21,22]. However, data suggests that vasoconstriction can still 
occur in the absence of adrenergic neurotransmission [22]. Nitric oxide (NO) is a 
potent vasodilator of vascular smooth muscle. It is created by nitric oxide 
synthase (NOS) and is released from the endothelial cells that line the VSM, 
causing vasodilation. Hodges et al. have demonstrated that the cold reflex 
inhibits NOS enzyme and other unclear mechanisms downstream in the NO 
system; thus, disrupting the normal vascular dilation [22]. Decreased arterial 
blood flow has been observed due to reflex vasoconstriction [8, 10, 13, 15, 22, 
31], most likely as a result of increased total peripheral resistance [8, 10]. 
Decreased blood flow to a localized area proves to be beneficial in the 
event of an injury [25,31]. Studies suggest that decreased blood flow from 
topical cryotherapies, such as menthol, consequently blunt local inflammatory 
response [23, 25]. Cryotherapy elicits a hepatic overexpression of interleukin-10 
(IL-10), an anti-inflammatory cytokine [23]. Hypothermic tissue response 
increases activation of the Janus kinase signaling cascade, resulting in 
overproduction of I L -10 via the STAT -3 cytokine transcription pathway [23]. 
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Normal response to soft tissue injury results in the hepatic transcription of 
inflammatory cytokines, such as tumor necrosis factor-a, via nuclear factor kappa 
B (NF-KB) separation from its inhibitory protein IKB [24]. However, the resulting 
hypothermic stimulation of IL-1 0 overexpression allows for the inhibition of NF-KB 
translocation by preventing the phosphorylation of IKB [23]. This mechanism 
provides the tissue protective properties of cold induced blood flow reduction. 
A study by Hollis et al. directly demonstrates the effects of menthol and ice 
on arterial blood flow reduction [13]. Subjects attended two morning trials 
approximately one week apart, during which forearm blood flow from the brachial 
artery was collected. Blood flow was measured for 15 minutes to serve as a 
baseline measure. Blood flow was measured continuously for 5 minutes before 
and for 10 minutes after the topical application of either ice or menthol ointment 
[13]. The remaining treatment was applied on the second visit. Mean arterial 
pressure was measured at baseline and throughout the entire treatment session 
to prevent distortions in blood flow due to blood pressure fluctuation. 
Hollis et al reported a significant time effect for ice and menthol treatments, 
but did not display any significant treatment interactions [13]. It was found that 
blood flow had been significantly (p<.05) reduced in both groups from baseline at 
60, 120, 180, 240, and 600 seconds post treatment. At 60 seconds the blood flow 
was reduced by approximately 43% compared to baseline, and by 24% for the 
rest of the testing period [13]. These findings suggest that menthol and ice cause 
similar significant reductions in blood flow, indicating that menthol is as effective 
as ice for arterial vasoconstriction. 
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Despite evidence supporting local arterial vasoconstriction after topical 
cryotherapy, some studies demonstrate increases in cutaneous blood flow after 
menthol application [12, 14]. Hong and Shellock found that with Eucalyptamint, a 
mentholated topical product, individuals displayed a 4 fold increase in cutaneous 
blood flow 5 minutes post application, with a slight gradual decrease until 45 
minutes post application when compared to baseline [14]. Skin and muscle 
temperature were measured via infrared thermometer and 25g thermistor needle, 
respectively. Skin temperature was measured every 5 minutes for 45 minutes, 
and had an average, significant change of 0.8 degrees C higher than the base 
temperature. Muscle temperature was significantly higher at 30 minutes post 
application as well [14]. Differences in methodology, such as treatment and 
location of blood flow measurement could be accountable for the discrepancies 
between data. It is possible that the increase in cutaneous cellular stimulation 
could elicit this increased flow, despite decreased flow to the local muscle tissue. 
Besides obvious differences in cutaneous and arterial blood flow, Eucalyptamint 
has several active ingredients that are not found in the other menthol ointments. 
During a previous study, our research team discovered that mentholated 
ointment elicits a statistically significant decrease in arterial blood flow, as well as 
an practically improved strength measurements [15]. During this study, subjects 
attended 3 experimental sessions approximately 1 week apart. Subjects 
received at random, either a topical ice pack, Biofreeze, or Control (no 
application) conditions applied to the underside portion of the forearm. During 
each of the three sessions, blood flow was measured at 5 minute intervals for 20 
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minutes via Phillips HOI 5000 Ultrasound Doppler (Seattle, WA). This was 
followed by 4 sets of 30 maximal concentric wrist extension/flexions on a Biodex 
System 3 dynamometer [15]. 
Statistical analysis demonstrated that radial arterial blood flow was 
markedly decreased after the first 5 minutes of the Biofreeze treatment, followed 
by a statistically significant increase in blood flow at 20 minutes, when compared 
to control condition [15]. However, treatment with a standard ice pack 
demonstrated a gradual decrease in blood flow, with significance occurring at 15 
minutes post treatment. These results suggest that a topical menthol product 
would be better suited for a situation that required short-term, immediate effects, 
such as a slight muscle injury or chronic joint pain, allowing an individual to 
experience a rapid recovery [15]. Nevertheless, these results further support the 
belief that topical cryotherapy is an effective arterial vasoconstrictor, regardless 
of its effects on cutaneous blood flow. 
The most interesting findings are the effects that the Biofreeze treatment 
had on strength performance. When compared to the ice and control conditions, 
Biofreeze elicited a statistically insignificant ( p= .83; p=.79; for flexion and 
extension respectively) increase in average peak strength across all 4 sets of 
extensions and flexions [15]. During the first set of each Biofreeze trial, flexion 
and extension strength were increased by approximately 18% and 14%, 
respectively, when compared to Control conditions. Even during the 4th and final 
set, the strength remained elevated by 8.5% and 13% respectively for 
flexion/extension [15]. 
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Although these findings are not statistically significant, increases in 
performance upwards of 8.5% may be practically significant in an athletic event. 
Due to the rapid increase in force production, these effects would most likely be 
due to increased neurological activity, and recent discoveries on the mechanistic 
actions of menthol could help support this concept. 
A topical neurological strength enhancement product would be a valuable 
asset to any individual looking to improve their athletic ability. Due to its rapid 
effects, it could be utilized shortly before sprinting, weight lifting, or any other 
power related events. Although overall strength enhancement could potentially 
be an effect, its already recognized pain relief properties could playa role in 
functional capacity as well. Kraemer et al. demonstrates that with the usage of a 
cetylated fatty acid - mentholated topical cream, 10 subjects suffering from 
arthritic pain in the knee, were able to improve the times of their stair climbing 
tests (14.85±6.3s pre; 13.05±5.3s post), as well as their up-and-go tests 
(9.37±2.9s pre; 8.22±2.4s post) to statistically significant levels after topical 
application 2 times daily for 1 week [3]. Although this is more likely due to pain 
alleviation rather than strength enhancement, this study suggests that menthol 
may enhance performance by preventing the physiological transduction of the 
nociceptive pain sensory pathway. 
However, many studies report that many terpene compounds, such as 
menthol, are extremely efficient at penetrating human skin, including the dermal 
and epidermal layers [32-36]. Terpenes are compounds that are typically derived 
from essential plan oils, making them rather lipophilic, which allows for easy 
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penetration of cellular membranes [36]. A range of 10 to 100 fold increases in 
skin permeation have been observed with the use of topical terpene products 
[36]. Menthol, in specific, has been show to be effective at skin penetration [34, 
35]. Martin et al. demonstrate that menthol can actually be measured in the 
bloodstream (19.0 ± 5.4 ng/mL) after topical patch application, and retains a half 
life of approximately 4.7 hours [34]. The penetration effects of topical menthol 
suggest that it may even alter intracellular mechanisms of muscle cells. 
As the skeletal muscle sarcolemma depolarizes, it stimulates the 
dihydropyridine - ryanodine receptor complex of the terminal cisternae, leading 
to a release of calcium ions from the sarcoplasmic reticulum into the sarcoplasm 
[37-39]. This intracellular influx is what eventually causes the excitation-
contraction coupling of muscle tissues. Phosphoinositides are phospholipids that 
are involved in this intracellular calcium release and regulation [37-42]. As stated 
earlier, menthol has been shown to sensitize TRPM8 calcium channels to 
PI(4,5)P2, causing channel activation and calcium influx [28]. PI(4,5)P2 and other 
similar phosphoinositides are found in muscle tissues throughout the body, 
including skeletal muscle [37-40, 43, 44]. Phosphoinositides are already known 
to activate TRP cation channels in pulmonary artery and aortic smooth muscle 
cells [40-42]. Menthol application to this muscle tissue evoked significant 
increases in intracellular calcium concentration [42]. Sensitization of calcium 
channels to these compounds may promote intracellular calcium influx in skeletal 
muscle tissue as well, provided menthol is present. This increase in calcium 
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could elicit an even greater force of muscle contraction, due to an increase in 
excitation-contraction coupling. 
An investigation examining the effects of topical menthol ointments, such 
as Biofreeze, on maximal muscle contraction could help clarify menthol's impact 
on performance. It is common knowledge that some of the strength gains due to 
neurological adaptations from training one limb are displayed in the contralateral 
limb during times of injury or other disuse. It is possible that the effects of 
menthol could display a systemic effect through the same or similar 
neuromuscular mechanism. Topical menthol's ability to enter the bloodstream [34] 




The purpose of this study is to determine the systemic and non-systemic 
effects of topical Biofreeze application on peak torque production and arterial 
blood flow. Heart rate and blood pressure will be measured to help determine 
mechanisms for these effects. Since no specific concentration of menthol has 
been deemed as the most effective, an experimental Biofreeze compound of 
10% menthol and the standard 3.5% menthol Biofreeze will be utilized to 
determine dosing effects. It is hypothesized that application of Biofreeze will 
cause an increase in peak torque production on the treated limb, and will cause 
lesser, yet still significant increases in the peak torque production of the non-
treated limb. It is also hypothesized that the increased concentration will lead to 




This study follows a randomized, repeated measures design. 8 male and 8 
female subjects, (mean age 24.2 ± 3.0 years), completed this study. Subjects 
were apparently healthy individuals, with no pre-existing cardiovascular disorders 
or limb injuries that could impact the results of the study, as assessed by a 
Medical History Questionnaire. Subjects were asked to participate in four 
sessions, approximately 1 week apart. Session 1 lasted approximately 30 
minutes, while sessions 2 through 4 lasted approximately 1 hour. 
During the first session, all subjects were consented for participation in the 
study using an informed consent document approved by the University of 
Louisville Institutional Review Board. Once consent was obtained, each subject 
was measured for demographic information by completing a demographic data 
collection sheet. This demographic sheet was administered at the beginning of 
the study and included age, gender, type and duration of exercise engaged in, 
and basic physical measurements. Basic physical measurements include the 3 
site Jackson-Pollock skin fold measurements and waist to hip ratio. 
A familiarization trial was also administered during the first session. 
Sample blood flow and strength measurements were demonstrated to the 
subjects in order to clarify the procedure. A single blood flow sample was taken 
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on each leg using the Philips HOI 5000 Ultrasound Doppler (Seattle, WA). Blood 
Pressure and Heart Rate measures were taken prior to the blood flow measure 
with an Omron automatic blood pressure cuff (Omron Healthcare Inc., Illinois). 
Subjects received a test run of one set per leg on the Biodex System 3 (Shirley, 
NY) dynamometer. No data was collected during the familiarization trial. 
A Philips HOI 5000 Ultra Sound Doppler (Seattle, WA) was used to 
quantify blood flow measures of the popliteal artery. Subjects were instructed to 
lie down in prone position and remain as still as possible on a padded table 
during blood flow collection. Using the automatic blood pressure cuff (Om ron 
Healthcare Inc., Illinois), heart rate and blood pressure measures were taken and 
recorded prior to the first blood flow measurement, and immediately after the 
second blood flow measurement. Once identified manually, the Doppler sensor 
head was positioned over the artery until the vessel could be accurately 
visualized on the device's video screen. The blood flow through the vessel was 
averaged over a full plot of arterial pulsations in order to determine the volume 
flow (ml/min) and arterial diameter (cm). Recorded arterial pulsations varied due 
to variations in subject heart rates. Pain measurements, based on a a to 10 scale 
(0 = no pain; 10 = worst pain imaginable), were taken after blood flow 
measurements to determine pain sensations elicited by menthol treatment. This 
same protocol was repeated on the contralateral leg immediately after successful 
completion of the ipsilateral side. 
During experimental sessions two through four, one of three randomly 
selected experimental applications was applied directly to the Ipsilateral (right) 
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thigh, with no treatment being administered to the contralateral (left) leg. 
Biofreeze (3.5% menthol), 10% Biofreeze (10% menthol), or control (no 
treatment) were the three treatment possibilities selected at random. The 
treatment was introduced immediately following baseline data collection. Due to 
the nature of the individual products, subjects were unable to be blinded to the 
administered treatments. However, subjects were blinded expected outcomes of 
the study. A pre-calculated amount of Biofreeze topical ointment was applied to 
the entire surface area of the subject's right thigh. A pilot subject was utilized to 
determine the quantity of Biofreeze needed to fully saturate their right thigh. 
Biofreeze ointment was applied topically 1 mL at a time until the leg was 
saturated with the ointment (subject mean = 7.0 ± 1.1 mL). Saturation was 
determined by the skins inability to quickly absorb the ointment. The length and 
circumference of the thigh were measured and applied to the cylinder surface 
area formula. Thigh measurements were taken from each consented subject, 
and the quantity of Biofreeze was extrapolated from the known pilot subject data. 
The concentrated Biofreeze was administered in a pre-packaged wipe 
form. Subjects were instructed to apply the menthol wipes in a clockwise fashion 
using even strokes. Wipes were continuously applied until the leg was saturated, 
which typically did not require more than 2 wipes total. Subjects were required to 
wear gloves during menthol application to avoid absorption into the hands. 
During the control condition no treatment was applied to the leg. 
Blood flow data was collected on the ipsilateral then contralateral leg 
before treatment and 5 minutes after the experimental application. Baseline 
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strength data was collected immediately following the baseline blood flow data 
collection using a Biodex System 3 dynamometer. The same protocol was 
repeated for trials two through four at the 15, 25 and 35 minute data collection 
points. A data collection time line for this protocol can be seen in figure 1. 
Each subject was seated and appropriately restrained on the Biodex 
System 3 dynamometer. The subjects were asked to complete 1 set of 3 
maximal voluntary knee extensions and flexions at a rate of 90 degrees per 
second. The Biodex System 3 manual recommends speeds of 60 degrees per 
second in a clinical setting, and 120 degrees per second for athletes. Since this 
study involved the general population, the median speed, 90 degrees per second, 
was the speed chosen for the protocol. In a study by Rothstein et aI., four 
isokinetic speeds (30, 60, 90, and 120 degrees per second) were tested to 
determine applied subject effort and force based on integrated electromyography 
(EMG) using an isokinetic dynamometer [45]. Their data demonstrated minimal 
differences in EMG activity based on rate isokinetic speed. This demonstrates 
that the selected isokinetic speed of 90 degrees per second will have minimal 
impact on the results of our peak torque readings. Range of motion was analyzed 
for each subject to account for individual variations in flexibility. This assessment 
was performed on the right and then the left leg. This same protocol was 
repeated for all 4 time trials. The 3 highest peak torque curves for flexion and 
extension were recorded to obtain the subject's maximum leg extension and 
flexion strength for both the right and left leg. The highest value recorded for 
each extension and flexion was then used for analysis of peak torque (N*m). 
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Collected data for blood flow and peak power was then analyzed for 
statistical significance using SPSS statistical software. Repeated measures 
analysis of variance (AN OVA) were calculated to determine the effect of the 
various treatments on blood flow and peak torque production over time. 




HEART RATE AND BLOOD PRESSURE 
Repeated measures analysis of variance (ANOVA) indicates a significant 
(F=15.432, p=.OOO) linear time effect on mean subject heart rate, with no 
significant time and treatment interaction present (see table 2). Post Hoc analysis 
indicates that the drop in Biofreeze (69.938 ± 3.204, 65.313 ± 2.648) and control 
(70.875 ± 3.204, 65.687 ± 2.648) trial heart rates are statistically significant 
between the pre and post treatment blood flow measurements. The 10% 
Biofreeze treatment demonstrates a decline in mean heart rate, but is not 
statistically significant (p>0.05) (see graph 1). No significant time or time and 
treatment interactions were observed with systolic blood pressure (F=0.078, 
p=0.781; F= 1.189, p=0.314) or diastolic blood pressure (F=0.425, p=0.518; 
F=1.198, p=0.311) for any trial. 
BLOOD FLOW AND ARTERIAL DIAMETER 
A significant time and treatment interaction (F=11.489, p=.OOO) is 
observed with blood flow in the treated popliteal artery (table 3). Least 
Significant Differences (LSD=16.39) reveals a decrease in blood flow during the 
3.5% Biofreeze trial (128.950±10.234; 1 03.669±1 0.940), while blood flow during 
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the control trial (114.625± 10.234; 141.025± 10.940) significantly increases (table 
4). No statistically significant change in blood flow was observed from 10% 
Biofreeze trial data when compared to Control or 3.5% Biofreeze treatments. 
However, the ability of the 10% Biofreeze treatment to demonstrate a slight, 
insignificant decrease in blood flow could be perceived as practically beneficial 
since it attenuates the typical blood flow response as displayed by the statistically 
significant increase in blood flow observed with the control treatment (graph 2). 
Blood flow data in the untreated popliteal artery demonstrates a significant 
time*treatment interaction (F=4.755; p=0.013). LSD analysis (LSD=16.8) 
indicates that 3.5% Biofreeze treatment results in a significant decline in left 
popliteal blood flow, with control trial almost breaching a significant increase 
(MD=16.369) (tables 5 and 6). The untreated popliteal artery demonstrates a 
similar pattern to the treated limb, with the 10% Biofreeze trial eliciting an 
insignificant decline in blood flow, as observed in the treated popliteal artery (see 
graph 3). 
Statistical analysis suggests that treated popliteal arterial diameter 
displayed a statistically significant time and treatment interaction (F=8.062, 
p=0.001) (table5). Both 3.5% Biofreeze (.751±.029; .708±.027) and 10% 
Biofreeze (.683±.029; .637±.027) treatment groups demonstrate significant 
declines in arterial diameter, or vasoconstriction (LSD=0.04). Control trial data 
elicits an increase in arterial diameter (.688±.029; .734±.027) which 
demonstrates vasodilation (tables 7 and 8, graph 4). No significant changes 
were observed in the arterial diameter of the untreated popliteal artery. 
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Pain measures taken during the two blood flow trials showed significance 
for time (F=15.666, p=O.OOO) and time treatment interactions (F=3.937, p=0.027). 
The pairwise comparisons analysis displays a significant mean difference 
(MD=.500) in pain, indicating an increase in pain for both 3.5% Biofreeze and 
10% Biofreeze trials over time. For the time treatment interaction, Least 
Significant Differences (LSD=0.46) suggests that pain sensation increases in 
3.5% Biofreeze and 10% Biofreeze groups when compared to control. (Data 
displayed in tables 9-11 ) 
Maximal Torque Production and Perceived Pain 
Repeated measures ANOVA reveals no significant time or time treatement 
interactions for any part of the Biodex trial. All treatments resulted in similar 
trends in peak torque production for Maximal Voluntary Extension and Flexion of 
the treated limb (graphs 5 and 6), and for the untreated limb (graphs 7 and 8), 
producing insignificant differences. 
Perceived pain data was collected for each leg after each completed set 
during the four trials to determine how menthol effects pain response to exercise. 





The purpose of this study was to investigate the effects of two different 
concentrations of menthol (3.5% and 10%) on: a) arterial blood flow in the treated 
leg. b) peak torque production in the treated leg. c) arterial blood flow and peak 
torque production in the untreated leg to determine if menthol is capable of 
producing systemic effects. d) changes in heart rate, blood pressure, and pain 
sensation. 
The results have produced several major findings. 1) Heart rate was 
significantly reduced during Control and 3.5% Biofreeze trials, but not in the 10% 
Biofreeze trial. 2) Blood flow to the treated limb was significantly reduced during 
3.5% Biofreeze trial and significantly elevated during Control. 3) Blood flow to 
the contralateral limb was significantly reduced by 3.5% Biofreeze treatment. 4) 
All 3 trials demonstrate significant changes in arterial diameter of the treated limb. 
5) Peak torque production was not influenced by treatment for either leg. 
HEART RATE 
Data collected during the blood flow portion of the protocol demonstrates 
mean heart rate reductions for all three trials, with a significant (p<0.05), 10% 
decrease in mean heart rate for Control and 6.6 % decrease for 3.5% Biofreeze 
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trials. 10% Biofreeze heart rate reduction was not significant, demonstrating a 
2.4% decrease. These results are expected given the vast quantity of research 
available on heart rate rebound effect after acute bouts of exercise. Some 
studies illustrate significant decreases in heart rate and blood pressure after 
acute bouts of low oxygen consumption (-30% V02 max) exercise [46, 47]. This 
supports our findings due to the 3 repetition maximal voluntary resistance bout 
that occurred between blood flow data collection pOints. However, this does not 
explicate the greater significant decrease observed in Control trial heart rate. 
One explanatory mechanism for this result is the increased adrenergic 
stimulation due to the sympathetic reflex associated with menthol application [19, 
21,22]. Increased sympathetic stimulation, therefore increased heart, would 
explain why a lesser rebound effect was observed in the two trials involving 
menthol treatment. With this mechanism originating in the skin, it makes sense 
that the more 10% Biofreeze displayed a non-significant decrease, unlike the 
standard 3.5% Biofreeze product. 
BLOOD FLOW AND ARTERIAL DIAMETER 
Blood flow and arterial diameter were both Significantly (p<0.05) 
decreased, 19.6% and 5.7% respectively, in the treated popliteal artery due to 
3.5% Biofreeze treatment. This agrees with the findings of other studies, which 
also expressed menthol induced decreases in arterial blood flow [13, 15, 22] and 
increased arterial vasoconstriction [19-22]. Previous work demonstrates that 
menthol is as effective as ice for decreasing blood flow [13]. Topical menthol and 
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ice treatments are known to excite 02C adrenergic receptors via sympathetic 
stimulation [19, 21] and inhibit the effects of the NOS enzyme [22], leading to 
arterial vasoconstriction. Some studies have shown that arterial vasoconstriction 
elicits decreases in mean arterial pressure for 20 minutes after application due to 
increases in total peripheral resistance (TPR) [8, 10]. This is not consistent with 
our findings, which indicate no significant changes in blood pressure for any trial 
during blood flow analysis. 
Control treatment resulted in statistically significant increases in blood flow 
and arterial diameter or the treated popliteal artery (23.0% and 6.6% 
respectively). This increase in blood flow and arterial diameter can be attributed 
to the maximal resistance exercise that occurred between blood flow trials. 
Arterial vasodilation normally occurs in response to exercise training, allowing for 
increased blood flow. Exercise induced vasodilation occurs due to nitric oxide 
release with increasing vascular shear stress [48]. This explains why lack of 
treatment resulted in increased arterial diameter and blood flow. Increased 
arterial diameter would indicate an overall decrease in TPR, which provides a 
larger stroke volume due to increased ventricular filling. Such an increase in 
stroke volume further supports why increased flow was observed, despite the 
significant decrease in Control heart rate. 
No significant effects were observed with blood flow of the ipsilateral limb 
due to 10% Biofreeze treatment. Nevertheless, the 10% Biofreeze results did 
follow the general trend of the 3.5% Biofreeze trial, with a 8.3% reduction in 
blood flow and a statistically significant decrease in arterial diameter of 6.7%. It is 
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difficult to explain why a more concentrated menthol product would display lesser 
results. Closer examination of the two Biofreeze products could explain this 
outcome. The Biofreeze gel (3.5% menthol) and Biofreeze wipes (10% menthol), 
contain many of the same compounds. However, the Biofreeze gel contains two 
ingredients, propylene glycol and glycerol, that are not found in the wipes. 
Studies have shown that propylene glycol and glycerol are very effective at 
increasing the absorption rate and permeability of topical products [49-51]. One 
study in particular demonstrates that propylene glycol increases the dermal 
translocation of hydrogel drugs [49]. This clearly supports why the product 
lacking these ingredients is less effective. 
In the contralateral artery, 3.5% Biofreeze treatment resulted in a 
statistically significant, 14.7% decrease in arterial blood flow. However, no 
significant changes in blood flow were found in the contralateral limb for Control 
or 10% Biofreeze treatments. Despite the lack of significance, Control and 10% 
Biofreeze treatments still displayed similar effects as observed in the treated leg, 
with Control group demonstrating a 15.2% increase in blood flow, which almost 
breaches statistical significance. 10% Biofreeze treatment elicits a 5.4% 
decrease in blood flow, which is similar to the 8.3% observed in the treated limb. 
These alterations in arterial blood flow support the concept that the sympathetic 
reflex from menthol causes an increase in TPR [8, 10], indicating a systemic 
effect of topical menthol application. Although the results are insignificant, 10% 
Biofreeze and 3.5% Biofreeze treatments decreased arterial diameter by 3.6% 
and 2.1 % respectively, while Control treatment increased arterial diameter by 
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2.5%. These results follow the same pattern as the treated limb, but to a lesser 
extent, indicating that the systemic effect is relatively mild. 
RESTING PAIN RESPONSE 
A significant increase in pain rating was observed during blood flow 
analysis for the 3.5% Biofreeze and 10% Biofreeze trials over time and when 
compared to Control. Menthol is known to elicit sensations of acute cold allodynia 
[11] by stimulation of thermal TRP channels [9, 16, 18, 28, 29]. This TRP channel 
stimulation creates an inhibitory effect on the A-delta nerve fibers, allowing for 
thermal transmission via C nociceptors [6-8, 10-12]. This demonstrates an 
increase in innocuous cold pain due to menthol application. 
MAXIMAL TORQUE PRODUCTION 
Results from the maximal voluntary extension and flexion trials did not 
agree with the hypothesized results. There were no significant differences 
between any of Biodex trials for any treatment, indicating that topical menthol 
products have no effect on peak torque production. These findings agree with our 
previous findings that display no stastically significant changes in peak torque 
production due to topical Biofreeze applications [15]. However, the treatment 
location and strength protocols are very dissimilar, which may be the cause of 
the insignificant increases observed previously. The other study applied 
Biofreeze treatment directly to the forearm instead of the thigh, and utilized sets 
of 30 repetitions with the forearm [15]. The much smaller muscle mass volume, 
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or differences in fiber type composition could have provided the observed results 
when testing the forearm. Whether menthol could reveal performance 
enhancement through its analgesic properties [1-3], allowing a person to feel less 
pain during exercise; or through its ability to cause calcium influx by activating 
skeletal muscle calcium channels [18, 28, 42], further investigation is necessary 




In conclusion, it is further supported that topical menthol causes a 
decrease in arterial blood flow by means of arterial vasoconstriction and 
increased total peripheral resistance. Although the results are less profound, it 
appears that menthol may actually cause a systemic reduction on blood flow. 
This study further supports menthol's actions on increased thermosensation, with 
significant increases in observed cold pain. It was also demonstrated that 
menthol concentration was not as important as the added ingredients to enhance 
its absorption. 3.5% Biofreeze displayed greater significance than 10% Biofreeze 
wipes in almost every category. This was likely attributed to the 3.5% Biofreeze's 
increased penetration due to its added ingredients, glycerol and propylene glycol. 
Menthol application displayed no apparent changes in performance. The 
known physiological effects make performance enhancements from topical 
menthol seem promising. Due to the nature of our measurements, our study was 
subject to human error and variation in subject effort. Therefore, further study is 
needed to confirm whether or not menthol impacts muscular performance. 
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Figure 1. Time Line of a Single Testing Session Which Includes Three Data 
Collection Points 
Baseline Data 5 Min Data 15 Min Data 35 Min Data 
Collection Collection Collection Collection 
- Blood flow - Blood Flow - Max leg ext/flex - Max leg ext/flex 
- Max leg ext/flex -HR and BP 
I - HR andBP - Observed Pain 
- Observed Pain 
I 25 Min Data 
I Collection 
Random - Max leg ext/flex 
AI1]2lication of 
- BioFreeze 
- Conc. BioFreeze 
- Control 
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Table 1. Descriptive Statistics 
D S escnptlve tatlstlcs 
N Minimum Maximum Mean Std. Deviation 
Age 16 22.00 35.00 24.1875 2.97139 
Height.lN 16 61.25 73.00 66.6094 3.43265 
Weight.LBS 16 113.00 221.00 157.5000 34.36083 
RestingHR 16 47.00 92.00 66.5000 13.20101 
RestingBP.SYS 16 105.00 143.00 121.7500 12.57776 
RestingBP.DIA 16 54.00 73.00 66.6250 5.48787 
BodyFatPercentage 16 5.90 28.00 17.9437 6.28267 
Waist.cm 16 60.00 85.00 72.8125 8.47914 
Hips.cm 16 91.00 110.00 98.0625 6.18028 
Aerobic Exercise. mi n 16 .00 410.00 200.7375 122.22126 
ResistanceExercise. min 16 .00 410.00 150.5125 125.37704 
Valid N (listwise) 16 
30 
Table 2. Significant time effect observed during Biofreeze and Control trials from 
baseline measure. 
Tests of Within-Subjects Contrasts 
Heart Rate: Initial Compared to 5 Minutes Post Application 
Source Time Type III Sum of 
Squares df Mean Square F Sig. 
Time Linear 341.260 1 341.260 15.432 .000 
Time * Treatment Linear 63.146 2 31.573 1.428 .250 
Error(Time) Linear 995.094 45 22.113 
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Graph 1. Heart rate response by treatment. Significant time effect observed 
during Control and Biofreeze trials from baseline measure. 
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Table 3. Right popliteal blood flow response to treatment. Significant 
time*treatment effect observed. 
Tests of Within-Subjects Contrasts 
Blood Flow Right Popliteal Artery 
Source Time Type III Sum of 
Squares df Mean Square F 
Time Linear 140.893 1 140.893 .291 
Time * Treatment Linear 11110.721 2 5555.361 11.489 





Table 4. Right popliteal blood flow response to treatment. Significant 
time*treatment effect observed during Biofreeze and Control Trials. 
LSD=16.39 
4. Treatment * Time 
BI d F 00 low Rigl t opllteal Artery h P r 
Treatment Time 95% Confidence Interval 
Mean Std. Error Lower Bound Upper Bound 
B 1 128.950 10.234 108.338 149.562 
2 103.669 10.940 81.634 125.703 
10% 1 100.913 10.234 80.301 121.524 
.-
2 92.525 10.940 70.491 114.559 
C 1 114.625 10.234 94.013 135.237 
2 141.025 10.940 118.991 163.059 
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Graph 2. Right popliteal arterial blood flow response to treatment. Significant 
time*treatment effect observed during Biofreeze and Control trials. 
* Indicates Significance at .05 alpha level 



























Table 5. Left popliteal blood flow response to treatment. Significant 
time*treatment effect observed. 
Tests of Within-Subjects Contrasts 
Blood Flow Left Popliteal Artery 
Source Time Type III Sum of 
Squares df Mean Square F 
Time Linear 138.000 1 138.000 .272 
Time * Treatment Linear 4822.834 2 2411.417 4.755 





Table 6. Left popliteal blood flow response to treatment. Significant 
time*treatment effect observed during Biofreeze trial. 
LSD=16.8 
4. Treatment * Time 
Blood Flow Le t Popliteal Artery 
Treatment Time 95% Confidence Interval 
Mean Std. Error Lower Bound Upper Bound 
B 1 121.556 10.523 100.362 142.750 
2 103.669 11.096 81.320 126.018 
10% 1 104.962 10.523 83.768 126.157 
-
2 99.288 11.096 76.938 121.637 
C 1 107.700 10.523 86.506 128.894 
2 124.069 11.096 101.720 146.418 
*Control approaching significance with Control Difference of 16.3 
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Graph 3. Left popliteal arterial blood flow response to treatment. Significant 
time*treatment effect observed during Biofreeze trial. 
* Indicates significance at .05 alpha level. 
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Table 7. Right Popliteal Arterial Diameter response to treatment. Significant 
time*treatment effect observed. 
Tests of Within-Subjects Contrasts 
Right Popliteal Arterial Diameter 
Source Time Type III Sum of 
Squares df Mean Square F Sig. 
Time Linear .005 1 .005 1.809 .185 
Time * Treatment Linear .043 2 .021 8.062 .001 
Error(Time) Linear .120 45 .003 
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Table 8. Right Popliteal Arterial Diameter response to treatment. Significant 
time*treatment effect observed in all treatments. (p<O.OS) 
LSD=.04 
4. Treatment * Time 
Right Popliteal Arterial Diameter 
Treatment Time 95% Confidence Interval 
Mean Std. Error Lower Bound Upper Bound 
B 1 .751 .029 .693 .808 
2 .708 .027 .655 .762 
10% 1 .683 .029 .625 .740 
.-
2 .637 .027 .583 .690 
C 1 .688 .029 .630 .746 
2 .734 .027 .680 .787 
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Graph 4. Right popliteal arterial diameter response to treatment. Significant 
time*treatment effect observed during all trials. 
* Indicates Significance at .05 alpha level 
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Table 9. Pain response to treatment during blood flow data collection. Significant 
time and time*treatment effect observed. 
Tests of Within-Subjects Contrasts 
Perceived Pain From Treatment DurinQ Blood Flow Data Collection 
Source Time Type III Sum of 
Squares df Mean Square F Sig. 
Time Linear 6.000 1 6.000 15.666 .000 
Time * Treatment Linear 3.016 2 1.508 3.937 .027 
Error(Time) Linear 17.234 45 .383 
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Table 10. Pain response to treatment during blood flow data collection. 
Significant time and time*treatment effect observed. 
Pairwise Comparisons 
erceive am unng 00 ow ata o ectlon PdP . D' BI d FI D C II 
(I) Time (J) Time 95% Confidence Interval for 
Mean Difference
8 
Difference (I-J) Std. Error Sig. 8 Lower Bound Upper Bound 
1 2 -.500 .126 .000 -.754 -.246 .. . 
2 1 .500 .126 .000 .246 .754 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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Table 11. Pain response to treatment during blood flow data collection. 
Significant time and time*treatment effect observed during Biofreeze and 10% 
Biofreeze trials. (p~0.05) 
LSD=.46 
4. Treatment * Time 
Perceived Pain Durina Blood Flow Data Collection 
Treatment Time 95% Confidence Interval 
Mean Std. Error Lower Bound Upper Bound 
B 1 .000 .000 .000 .000 
2 .781 .219 .341 1.222 
10% 1 .000 .000 .000 .000 
.-
2 .719 .219 .278 1.159 
C 1 .000 .000 .000 .000 
2 1.110E-16 .219 -.441 .441 
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Graph 5. Right leg maximal voluntary extension response to treatment. No 
Significance observed. 



















Graph 6. Right leg maximal voluntary flexion. No significant effects observed. 
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Graph 7. Left leg maximal voluntary extension. No significant effects observed. 






















Graph 8. Left leg maximal voluntary flexion. No significant effects observed. 
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Methods, Substance abuse and Human Health, 
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Epidemiology, Health and Fitness Assessments and 
Exercise Prescription, Health Behavior Change, Health 
Psychology, Stress and Human Health, Sexuality and 
Human Health, Women's Health, Essentials of Nutrition, 
Communications, Spanish to level 4 
Computer Skills: Microsoft Office, SPSS 
PROFESSIONAL EXPERIENCE 
Graduate ResearchfTeaching Assistant, University of 
Louisville 
Louisville, KY 08/08 - Present 
Data collection and analysis 
Protocol development and submission 
Subject recruiting and scheduling 
Anatomy and Physiology course assistance and instruction 
Graduate Lab Methods course assistant 
Fitness Consultant/Personal Trainer, Riverside Health Care 
Bourbonnais, IL 05/08 - 08/08 
Perform Fitness Assessments 
Give equipment orientations 
Develop various fitness programs 
Assist with membership and sales 
Personal training 
Assistant Manager and Personal Trainer, Levee Plaza 
Health and Fitness 
West Lafayette, IN 05/06 - 05/08 
Help patrons with membership needs and questions. 
Maintained a clean environment for patrons to workout in. 
Supervise employees during the evening hours. 
Educate patrons about proper equipment usage 
Personal TrainerlFitness Advisor, Purdue University Colby 
Fitness Center 
West Lafayette, IN 01/06-08/07 
Interacted with clients by providing a solid workout schedule 
Instructed the patrons with proper exercise form and 
technique 
Educated clients about the importance of physical activity. 
Perform standard fitness tests on clients to determine health 
status. 
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Student Assistant, Purdue University WorkLife Programs 
West Lafayette, IN 02/07 - 07/07 
Assisted with overall organization of a program titled 
Targeted Communication. 
Helped organize mass mailings for the Targeted 
Communication program. 
Helped to lead patrons through a walking program. 
Assisted in numerous other office related tasks 
Head Fitness Center Supervisor, Purdue University Colby 
Fitness Center 
West Lafayette, IN 01/05 - 11/05 
Insured the safety of patrons. 
Organized the fitness center staff duties and schedules 
Performed duties such as Payroll and kept track of the 
number of patrons. 
Personal Trainer and Supervisor, Harrison Barbell Fitness 
Center 
Harrison,OH 05/05 - 08/05 
Interacted with clients by providing a solid workout schedule 
and diet. 
Instructed the patrons with proper form and technique of 
exercises. 
Assisted in the organization of the gym as well as the 
patrons memberships. 
ACTIVITIES AND HONORS: 
Graduate Student Council Representative 
I am currently the student representative for the Health and 
Sports Sciences Department on the Graduate Student 
Council at the University of Louisville. Meetings discuss 
issues related to graduate student activities, primarily travel 
funds. In February 2009, I organized the graduate student 
funding procedures for the exercise physiology departments 
trip to the Southeast ACSM conference. 
Hallowellness Health Fair Committee Board Member 
I assisted in the organization of the entire health fair from the 
beginning to the end of October 2005 at the Purdue 
University Division of Recreational Sports. During this Health 
Fair I organized displays and recruited volunteers in order to 
allow the fair to run smoothly. 
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Fitness Center Supervisor Employee of the Year 
This is an honorary reward that I received from the Purdue 
University Division of Recreational Sports in May of 2005, 
which recognized my dedication to the job I held as a Fitness 
Center Supervisor in the Colby Fitness Center. 
Infant/Child/Adult First Aid and CPR/AED Certified 
I am certified by the American Red Cross 
Student Lab Assitant, Purdue University Wastl Exercise 
Physiology Lab 
I am currently voluntarily assisting with research in the Wastl 
Exercise Physiology lab in the basement of Lambert Hall, 
primarily dealing with carbohydrate studies. I assist in 
preparation procedures as well as various techniques during 
the V02 max tests, including blood collection and analysis. 
ACSM Member 
I am currently a student member of the National and 
Southeast American College of Sports Medicine 
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